ELISA with Biotinylated Human IgE Protein 2182

Biotinylated Human IgE Protein 2182

$525.00 – $1,750.00

Summary

Expression: HEK293
Functional: Yes (ELISA)
Amino Acid Range: Cys209-Lys428

SKU: 2182parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
express system	HEK293
product tag	C-His-Avi
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.
molecular weight	The protein has a predicted MW of 27.8 kDa. Due to glycosylation, the protein migrates to 32-38 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Biotinylated Human IgE Protein 2182

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.
Protein names Immunoglobulin heavy constant epsilon (Ig epsilon chain C region) (Ig epsilon chain C region ND)
Gene names IGHE,IGHE
Mass 9606Da
Function Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).; [Isoform 1]: Constant region of secreted IgE, also known as the Fc region of IgE antibody. Mediates IgE effector functions on myeloid and lymphoid cells primarily via two Fc receptors, the high-affinity IgE Fc receptor complex/FCER1A:MS4A2:FCGR1A and the low-affinity FCER2 receptor, which upon antigen/allergen cross-linking initiate signaling pathways that lead to immune cell activation and differentiation (PubMed:2167225, PubMed:25629393, PubMed:33840121, PubMed:7544003, PubMed:8114916, PubMed:8551243). Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions (PubMed:25629393, PubMed:33840121, PubMed:7544003, PubMed:8114916, PubMed:8551243). Stimulates the high-affinity IgE Fc receptor complex/FCER1A:MS4A2:FCGR1A on mast cells, basophils and eosinophils leading to secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes (PubMed:25629393, PubMed:8114916, PubMed:8551243). On macrophages, cross-linking of FCER2 by IgE immune complexes induces intracellular killing of parasites through activation of L-Arginine-nitric oxide pathway (PubMed:7544003). Activates macrophages to kill tumor cells via antigen-specific antibody-dependent cytotoxicity (ADCC). Triggers differentiation of quiescent M0 macrophages toward M1 state and reprograms M2 macrophages toward a proinflammatory state with antitumor functions (PubMed:30956175). Stimulates FCER2 on B cells and initiates IgE-dependent antigen uptake and presentation to T cells (PubMed:2167225).; [Isoform 2]: Constant region of membrane-bound IgE (long mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking triggers quick BCR signaling, ensuring survival of IgE-switched B cells and differentiation into plasma cells, thus regulating both primary and memory IgE responses.; [Isoform 3]: Constant region of membrane-bound IgE (short mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking initiates slower but sustained BCR signaling that negatively regulates mature B cell proliferation.
Subellular location [Isoform 1]: Secreted .; [Isoform 2]: Cell membrane ; Single-pass type I membrane protein .; [Isoform 3]: Cell membrane ; Single-pass type I membrane protein .
Tissues [Isoform 2]: Expressed in B lymphocytes stimulated with IL4 and CD40.
Structure The basic structural unit of both sIgE and mIgE molecules consists of two identical heavy chains and two identical light chains; disulfide-linked. N-terminal variable regions of the heavy and light chains form the antigen binding sites, whereas the C-terminal constant regions of the heavy chains interact with immune receptors to mediate effector functions.; [Isoform 1]: Part of IgE antibody (PubMed:7995941). Interacts (via CH3) with the alpha chain/FCE1RA of IgE Fc receptor complex (PubMed:10917520). Interacts (via CH3 region) with FCER2 (via C-type lectin domain); this interaction regulates IgE homeostasis (PubMed:16172256).; [Isoform 2]: Part of IgE B cell antigen receptor complex (BCR). The BCR complex consists of one mIgE molecule responsible for antigen binding, non-covalently associated with CD79A and CD79B signaling chains.; [Isoform 3]: Part of IgE B cell antigen receptor complex (BCR). The BCR complex consists of one mIgE molecule responsible for antigen binding, non-covalently associated with CD79A and CD79B signaling chains.
Target Relevance information above includes information from UniProt accession: P01854
The UniProt Consortium

ELISA with Biotinylated Human IgE Protein

Immobilized Biotinylated Human IgE, His Tag at 0.5µg/ml (100µl/Well) on the streptavidin precoated plate (5µg/ml). Dose response curve for Anti-IgE Antibody, hFc Tag with the EC50 of 5.0ng/ml determined by ELISA.

The purity of Biotinylated Human IgE is greater than 95% as determined by SEC-HPLC.

SDS-PAGE gel of Biotinylated Human IgE Protein

Biotinylated Human IgE on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.